Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00617929 2017-12-28

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Phase 2 Terminated

12 enrolled 12 charts

BreastCNSGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Phase 2 Completed

20 enrolled 6 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

NCT00250718 2015-08-03

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2 Terminated

17 enrolled 4 charts

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

NCT00131313 2005-08-18

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Phase 4 Unknown

180 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

MINUTE

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Split-Dose R-CHOP for Older Adults With DLBCL

VIWA-1

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

SPINOZA

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.